血液恶性瘤中CAR-T细胞治疗的局限性:专注于抗原逃逸和T细胞功能障碍
Yanyu Lin1, Shuqi Luo1, Jianhui Wei1
1Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Qishan Campus, Fujian Normal University, Fuzhou 350117, China.
International journal of molecular sciences
|October 16, 2025
概括
化学抗原受体T (CAR-T) 细胞疗法对血液癌症有希望,但面临着抗原逃逸等挑战. 新的策略,包括多向的CAR-T细胞,正在开发中,以提高长期治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体T (CAR-T) 细胞疗法已经改变了血液恶性瘤治疗.
- 长期的CAR-T疗效受到抗原逃逸和T细胞功能障碍的限制.
研究的目的:
- 审查目前在血液恶性瘤中CAR-T治疗的局限性.
- 讨论提高CAR-T疗效的新兴策略.
主要方法:
- 审查了解CAR-T机制的近期进展.
- 分析新的CAR-T工程技术和治疗目标.
主要成果:
- 抗原逃逸和T细胞功能障碍是CAR-T疗法的关键障碍.
- 多重向和工程化的CAR-T细胞在克服抵抗和复发方面表现有前途.
结论:
- 先进的CAR-T工程,新的目标和多目标策略对于改善治疗结果至关重要.
- 解决抗原逃逸和T细胞功能障碍对于血液恶性瘤中持久的CAR-T反应至关重要.
相关概念视频
01:40Cell-mediated Immune Responses
83.4K
Overview
83.4K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:22T Cell Activation and Clonal Selection
14.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.7K